Research programme: VAP-1 inhibitors - Sucampo Pharmaceuticals

Drug Profile

Research programme: VAP-1 inhibitors - Sucampo Pharmaceuticals

Alternative Names: RTU-009

Latest Information Update: 09 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator R-Tech Ueno
  • Developer Sucampo Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action AOC3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cerebral infarction; Graft-versus-host disease

Most Recent Events

  • 07 Dec 2015 R-Tech Ueno has been acquired and merged into Sucampo Pharmaceuticals
  • 08 Jun 2015 Preclinical trials in Cerebral infarction (Combination therapy) in Japan (IV)
  • 08 Jun 2015 Preclinical trials in Graft-versus-host disease (Adjunctive treatment) in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top